Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -393.68% is 284% below its 5-year average of -102.52%, near the low end of its 5-year range (-393.68%–-49.01%).
102.22% below its 12-month average of -194.68%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -123.09%.
RETURN ON ASSETS (ROA)
-393.68%
RETURN ON ASSETS (ROA) AVG TTM
-194.68%
RETURN ON ASSETS (ROA) AVG 3Y
-123.06%
RETURN ON ASSETS (ROA) AVG 5Y
-102.52%
RETURN ON ASSETS (ROA) AVG 10Y
-109.11%
RETURN ON ASSETS (ROA) AVG 15Y
-83.86%
RETURN ON ASSETS (ROA) AVG 20Y
-77.16%
CURRENT VS TTM AVG
-102.22%
CURRENT VS 3Y AVG
-219.90%
CURRENT VS 5Y AVG
-284.01%
CURRENT VS 10Y AVG
-260.82%
CURRENT VS 15Y AVG
-369.46%
CURRENT VS 20Y AVG
-410.19%
SECTOR MEDIAN · HEALTHCARE
-30.84%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-1176.32%
vs the sector median at left
Oncolytics Biotech Inc.
Market Cap
$59.66M
Return on Assets (ROA)
-393.68%
TTM Avg
-194.68%
3Y Avg
-123.06%
5Y Avg
-102.52%
Market Cap
$59.75M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$60.08M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$58.57M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$60.86M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$61.04M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$61.34M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$57.54M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$56.98M
Return on Assets (ROA)
-42.67%
TTM Avg
-85.33%
3Y Avg
-379.34%
5Y Avg
-281.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $59.66M | -393.68% | -194.68% | -123.06% | -102.52% |
| PDS Biotechnology Corporation (PDSB)vs › | $59.75M | -382.32% | -98.02% | -80.35% | -65.77% |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.08M | -118.15% | -138.13% | -224.99% | -221.92% |
| Fractyl Health, Inc. (GUTS)vs › | $58.57M | -128.88% | -89.84% | -89.26% | -80.42% |
| Adicet Bio, Inc. (ACET)vs › | $60.86M | -66.80% | -56.95% | -50.95% | -40.99% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $61.04M | -98.94% | -57.19% | -57.75% | -128.29% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.34M | -44.47% | -42.63% | -230.85% | -167.04% |
| Boundless Bio, Inc. (BOLD)vs › | $57.54M | -37.05% | -34.36% | -41.63% | -37.74% |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | -42.67% | -85.33% | -379.34% | -281.82% |
| InterCure Ltd. (INCR)vs › | $63.02M | -5.05% | -7.03% | -4.31% | -4.67% |
ROA
-393.7%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -276.44% |
| 2024-12-31 | -112.91% |
| 2023-12-31 | -53.89% |
| 2022-12-31 | -49.01% |
| 2021-12-31 | -57.33% |
| 2020-12-31 | -65.53% |
| 2019-12-31 | -231.73% |
| 2018-12-31 | -114.61% |
| 2017-12-31 | -86.04% |
| 2016-12-31 | -102.59% |
| 2015-12-31 | -50.11% |
| 2014-12-31 | -108.29% |
| 2013-12-31 | -83.38% |
| 2012-12-31 | -164.75% |
| 2011-12-31 | -80.62% |
| 2010-12-31 | -44.95% |
| 2009-12-31 | -45.60% |
| 2008-12-31 | -125.47% |
| 2007-12-31 | -50.82% |
| 2006-12-31 | -42.60% |
| 2005-12-31 | -27.61% |
| 2004-12-31 | -32.81% |
| 2003-12-31 | -32.80% |
| 2002-12-31 | -33.90% |
| 2001-12-31 | -32.36% |
| 2000-12-31 | -16.68% |
| 1999-12-31 | -8.02% |
